Tzield Accepted for Priority FDA Review
There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay…
There’s good news on the horizon for people at risk for a type 1 diabetes (T1D) diagnosis, especially parents of young children. Sanofi recently announced that its drug to delay…
The FDA has accepted for priority review a supplemental biologics license application (sBLA) for teplizumab-mzwv (Tzield; Sanofi) that seeks to expand the current age indication from 8 years and older…
MedWatchUS FDA grants priority review for Sanofi’s type 1 diabetes drugFrance is seeking fast-track approval of diabetes drug Tzield in children aged over one..2 hours ago
Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the…